Merck & Co (NY: MRK )

128.97 +1.67 (+1.31%)
Official Closing Price Updated: 4:10 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,047,296
Open 127.61
Bid (Size) 128.66 (1)
Ask (Size) 129.16 (2)
Prev. Close 127.30
Today's Range 127.59 - 129.12
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.26%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
Via Benzinga

Performance

YTD
+13.89%
+13.89%
1 Month
-1.92%
-1.92%
3 Month
+1.75%
+1.75%
6 Month
+8.51%
+8.51%
1 Year
+18.65%
+18.65%

More News

Read More
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
Via InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Via Talk Markets
Topics Stocks
Exposures US Equities
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Merck & Co Unusual Options Activity
Via Benzinga
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Via Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Via InvestorPlace
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
Via InvestorPlace
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
Via Benzinga
Exposures COVID-19
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Merck Stock On Monday?
Via Benzinga
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
From Merck & Co., Inc.
Via Business Wire
3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt
Via InvestorPlace
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
Via InvestorPlace
What's Going On With Merck Stock On Friday?
Via Benzinga
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.